Management of Hyperparathyroidism and Anemia

Initial Diagnostic Workup

The American Journal of Kidney Diseases recommends measuring serum calcium with PTH levels simultaneously to determine whether the patient has primary or secondary hyperparathyroidism, as management differs substantially 1
The National Kidney Foundation suggests checking kidney function (serum creatinine, eGFR) to identify chronic kidney disease (CKD), the most common cause of secondary hyperparathyroidism, which fundamentally changes the treatment approach 2, 1
The National Institutes of Health recommends assessing 25-OH vitamin D levels, with a target of >20 ng/ml (50 nmol/L), as vitamin D deficiency commonly drives secondary hyperparathyroidism and worsens anemia 3, 1
The American Journal of Kidney Diseases advises evaluating iron status before any erythropoietin therapy, checking complete iron panel (ferritin, transferrin saturation, TIBC), as iron deficiency must be corrected first 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initiating or increasing active vitamin D sterols (calcitriol, alfacalcidol, paricalcitol, or doxercalciferol) to reduce PTH to target range of 150-300 pg/mL in dialysis patients 1
The National Kidney Foundation suggests reducing or discontinuing phosphate supplements while increasing active vitamin D, as this combination optimally suppresses PTH without worsening hypercalcemia 3, 1
The American Society for Bone and Mineral Research recommends supplementing with native vitamin D (cholecalciferol or ergocalciferol) if 25-OH vitamin D is <20 ng/ml 3, 1

The American Journal of Kidney Diseases defines anemia as hemoglobin <13.0 g/dL in males, <12.0 g/dL in females, and recommends ensuring adequate iron stores before erythropoietin therapy 5, 6
The National Kidney Foundation advises initiating erythropoietin (Epoetin alfa) only after iron stores are adequate, PTH is being actively treated, and other causes excluded (folate deficiency, hypothyroidism, aluminum toxicity, hemoglobinopathies) 2

The American Journal of Kidney Diseases recommends monitoring serum calcium and phosphorus every 2 weeks for 1 month after initiation or dose adjustment, then monthly, and measuring PTH monthly for at least 3 months, then every 3 months once target achieved 1